2023-10-02-世界卫生组织-A_H3N8_-_Southern_hemisphere_2024_2页_172kb

Summary of A(H3N8) Candidate Vaccine Viruses and Potency Testing Reagents

Core Content

This document provides an overview of the status of development and availability of A(H3N8) candidate vaccine viruses (CVVs) and potency testing reagents as of 3 October 2023. It is part of the WHO Global Influenza Surveillance and Response System (GISRS), which conducts antigenic and genetic analyses to support vaccine development.

Main Points

1. Candidate Vaccine Viruses in Preparation

• A/Henan /4-10CNIC/2022:
  • Antigenic prototype: A/Henan /4-10CNIC/2022
  • Clade: Eurasian Lineage
  • Type of virus or reassortant: Reverse genetics
  • Developing Institute: CDC/CCDC
  • Availability status: Pending

2. Reference Antigens (Freeze-Dried)

• The table outlines the reference antigens used for potency testing.
• It includes information on the parent virus, starting materials (CVV or Egg/Cell), reference antigen/lot number, unitage (μgHA/mL), and availability.
• The table is to be updated and currently contains no data entries.

3. Sheep Antisera

• The table details purified hemagglutinin (HA) from parent viruses and egg or cell sources.
• It also includes order details and availability.
• The table is to be updated and currently contains no data entries.

4. Anti NA Serum

• A specific anti-NA serum is available for tests to identify neuraminidase activity.

Key Information

• WHO Collaborating Centres are responsible for antigenic and genetic analyses of candidate vaccine viruses.
• The composition and formulation of vaccines used in each country are approved by national or regional control authorities.
• The status of A(H3N8) CVVs is currently limited, with only one candidate virus in preparation.
• The availability of reference antigens and sheep antisera is not yet fully detailed, indicating ongoing updates and development.
• Contact information for relevant institutes is provided to facilitate orders and inquiries.

Contact Details

• CCDC (Chinese Center for Disease Control and Prevention): whocc-china@cnic.org.cn
• CDC (Centers for Disease Control and Prevention, USA): nmb7@cdc.gov (Subject: CVV request)
• MHRA (UK Medicines and Healthcare products Regulatory Agency): standards@nibsc.org or enquiries@nibsc.org
• SJCRH (St. Jude Children's Research Hospital): richard.webby@stjude.org
• WHO Collaborating Centres: https://www.who.int/initiatives/global-influenza-surveillance-and-response-system/who-collaboration-center-erl
• General Enquiries: gisrs-whohq@who.int
• Additional Information: For other type and subtype candidate vaccine viruses and potency testing reagents, visit https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/zoonotic-influenza-viruses-and-candidate-vaccine-viruses